Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 3/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 2/20 | 0.41 |
| ▸ | CSF1R | P07333 | 1/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | FLT1 | P17948 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.41 |
| ▸ | CDK8 | P49336 | 1/20 | 0.41 |
| ▸ | GSK3A | P49840 | 1/20 | 0.41 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.41 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.41 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 2/20 | 0.40 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4705654 | 0.91 | PDE4B (0.80) | PDE4BSMN1; SMN2TP53 | |
| SCHEMBL4706133 | 0.90 | PDE4B (0.85) | PDE4BSMN1; SMN2GSK3BCSF1RFGFR1 | |
| SCHEMBL4707226 | 0.89 | PDE4B (0.67) | PDE4BSMN1; SMN2GSK3BCSF1RFGFR1 | |
| SCHEMBL4708322 | 0.88 | PDE4B (0.90) | PDE4BSMN1; SMN2GSK3BCSF1RFGFR1 | |
| SCHEMBL4707595 | 0.88 | PDE4B (0.82) | PDE4BSMN1; SMN2GSK3BCSF1RFGFR1 | |
| SCHEMBL4707416 | 0.87 | PDE4B (0.80) | PDE4BSMN1; SMN2GSK3BCSF1RFGFR1 | |
| SCHEMBL4706447 | 0.87 | PDE4B (0.80) | PDE4BSMN1; SMN2GSK3BCSF1RFGFR1 | |
| SCHEMBL4708776 | 0.87 | PDE4B (0.80) | PDE4BSMN1; SMN2GSK3BCSF1RFGFR1 | |
| SCHEMBL4708354 | 0.87 | PDE4B (1.00) | PDE4BSMN1; SMN2GSK3BCSF1RFGFR1 | |
| SCHEMBL4708696 | 0.87 | PDE4B (0.80) | PDE4BSMN1; SMN2GSK3BCSF1RFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7459453-B2 | Pyridazin-3(2H)-one derivatives as PDE4 inhibitors | LABORATORIOS ALMIRALL, S.A. (ES) | 2008-12-02 | — | — | US | claimed |
| US-20060052379-A1 | Pyridazin-3(2h)-one derivatives as pde4 inhibitors | LABORATORIOS ALMIRALL, S.A. (ES) | 2006-03-09 | — | — | US | claimed |
| US-20080269235-A1 | PYRIDAZIN-3 (2H) -ONE DERIVATIVES AS PDE4 INHIBITORS | DAL PIAZ VITTORIO | 2008-10-30 | — | — | US | disclosed |
| EP-1503992-A1 | PYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE4 INHIBITORS | Almirall Prodesfarma, S.A. (ES) | 2005-02-09 | — | — | EP | disclosed |
| WO-2003097613-A1 | PYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE4 INHIBITORS | ALMIRALL PRODESFARMA SA (ES) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269235-A1 | PYRIDAZIN-3 (2H) -ONE DERIVATIVES AS PDE4 INHIBITORS | PDE4A, PDE3A, PDE4B | PDE4B 3/4885SMN1; SMN2 2927/4885GSK3B 565/4885 |
| US-20060052379-A1 | Pyridazin-3(2h)-one derivatives as pde4 inhibitors | PDE4A, PDE3A, PDE4B | PDE4B 3/4885SMN1; SMN2 2927/4885GSK3B 565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.